期刊
EXPERT REVIEW OF HEMATOLOGY
卷 8, 期 5, 页码 569-579出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/17474086.2015.1061427
关键词
bruton tyrosine kinase; ibrutinib; immunoglobin M; lymphoplasmacytic lymphoma; Waldenstrom macroglobulinemia
类别
资金
- Millenium Celgene Binding Site Onyx Med Learning Group Research to Practice
Waldenstrom macroglobulinemia (WM) is a B-cell non-Hodgkin lymphoma (NHL) characterized by IgM monoclonal gammopathy and bone marrow infiltration by lymphoplasmacytic cells. Until recently, there was no drug specifically approved for WM by the US FDA, leading to wide variations in therapeutic strategies across the globe. Ibrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, is the first drug approved specifically for WM by the FDA after a clinical trial showed impressive response in previously treated WM. Ibrutinib is a non-stem cell toxic and non-neurotoxic option and suitable for long-term oral maintenance therapy, with the potential of improving survival in WM. With identification of novel genetic mutations impacting response to ibrutinib, it would be possible to individualize therapy based on MYD88 and CXCR4 genotypes. However, long-term safety and efficacy data are required, and cost-effectiveness needs to be addressed before ibrutinib can gain widespread acceptance for front-line therapy of WM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据